Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

We all age. And while humanity's life expectancy has increased dramatically in the modern era, we still struggle with the ...

The NHS will provide the monoclonal antibody Crysvita at 20 specialist centres across England for patients with XLH.

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Refeyn, the company behind pioneering mass photometry technologies, has developed and launched a custom software platform ...

Cancer is a disease in which mutated cells grow rapidly and uncontrollably. Unfortunately, these cells resist the body’s ...

For example, this technology can be used to increase an antibody’s affinity for a therapeutic target while decreasing its affinity for other biomolecules, which could increase potency and ...

Global Bispecific Antibody Is Expected To Surpass US$ 40 Billion By 2029 Says Kuick ResearchDelhi, Nov. 25, 2024 (GLOBE NEWSWIRE) -- In Nov ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.